Metallo-beta-lactamase domain-containing protein 1 (MBLAC1)

Metallo-beta-lactamase domain-containing protein 1 (MBLAC1) is a cytoplasmic and nuclear endoribonuclease belonging to the metallo-beta-lactamase superfamily. It catalyzes the hydrolysis of replication-dependent histone pre-mRNA 3'-ends, which is essential for proper histone mRNA maturation during S-phase and required for cell cycle progression[1][2][3][6]. MBLAC1 mediates site-specific cleavage downstream of the stem-loop in histone pre-mRNAs and prevents non-specific mRNA degradation via recognition elements. Its activity is tightly linked to cell proliferation and may be involved in oncogenic processes[2]. MBLAC1 is also identified as a high-affinity binding partner for the drug ceftriaxone in the CNS, with potential implications for neurological conditions and as a pharmacological target for regulating glial glutamate transporter expression[5][7]. Current research positions MBLAC1 as a promising therapeutic target, but its clinical roles, mechanistic links to disease, and potential safety concerns require further validation and investigation.

Other names

Endoribonuclease MBLAC1metallo-beta-lactamase domain containing 1MGC49416MBLC1MBL domain containing protein 1Metallo-beta-lactamase domain-containing protein 1

Inhibition or modulation of RNA endonuclease activity, leading to altered histone mRNA processing and cell cycle effects; Ceftriaxone: binds specifically and with high affinity to MBLAC1, potentially altering cell cycle or neurotransmitter transporter activities (not classical enzyme inhibition, but a regulatory interaction)